The filing indicates an officer intends to sell a modest number of shares. Monitor for actual sale execution on Form 4; the amount is small relative to typical market cap and likely routine post-vesting diversification.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $6.60entry
- T+1 · 8d ago +3.87%α +1.50% · $6.85
- T+5 · 4d ago −5.84%α −8.43% · $6.21
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Namrata Saroj, an officer of Ocular Therapeutix, filed a Form 144 notice of intent to sell 35,370 shares of common stock, with an approximate market value of $231,836. The shares were acquired through restricted stock vesting under a registered plan on November 4, 2026. The filing signals a planned sale but does not confirm execution.
Key Facts
- Insider Namrata Saroj (officer) filed Form 144 to sell 35,370 shares
- Approximate sale value: $231,836
- Shares acquired via restricted stock vesting under a registered plan on 11/04/2026
- Proposed sale date: 11/05/2026
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
Financial Impact
35,370 shares, approximately $231,836 based on filing estimate
Risk Factors
- Form 144 is an intent to sell; the sale may not occur
- No context on insider's total holdings or prior selling patterns provided
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010732 |
| Document: 0001950047-26-010732-index.html | 0001950047-26-010732 |
| Document: 0001950047-26-010732.txt | 0001950047-26-010732 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Viewing Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers